Immunogenicity and safety of seasonal influenza vaccines in children under 3 years of age

References

• Javanian M, Barary M, Ghebrehewet S, et al. A brief review of influenza virus infection. J Med Virol. 2021;93(8):4638–4646.
   PubMed Web of Science ®Google Scholar
• Chen J, Wang J, Zhang J, et al. Advances in development and application of influenza vaccines. Front Immunol. 2021;12:711997.
   PubMed Web of Science ®Google Scholar
• World Health Organization. (‎2017)‎. The immunological basis for immunization series: module 23: influenza vaccines [cited 2023 Feb 23]. Available from: https://apps.who.int/iris/handle/10665/259211
   Google Scholar
• Smith W, Andrewes CH, Laidlaw PP. A virus obtained from influenzae patients. Lancet. 1933;222(5732):66–68.
   Google Scholar
• Stanley WM. The preparation and properties of influenza virus vaccines concentrated and purified by differential centrifugation. J Exp Med. 1945;81(2):193–218.
   PubMed Web of Science ®Google Scholar
• Hardelid P, Rait G, Gilbert R, et al. Recording of influenza-like illness in UK primary care 1995-2013: cohort study. PLoS One. 2015;10(9):e0138659.
   PubMed Web of Science ®Google Scholar
• UK Health Security Agency. Weekly national influenza and COVID-19 report: week 27 report. 2022. https://www.gov.uk/government/statistics/national-flu-and-covid-19-surveillance-reports-2021-to-2022-season
   Google Scholar
• Hardelid P, Rait G, Gilbert R, et al. Factors associated with influenza vaccine uptake during a universal vaccination programme of preschool children in England and wales: a cohort study. J Epidemiol Community Health. 2016;70(11):1082–1087.
   PubMed Web of Science ®Google Scholar
• UK Health Security Agency. Seasonal influenza vaccine uptake in children of school age: winter season 2020 to 2021 [cited 23 Feb 2023]. Available from: https://www.gov.uk/government/statistics/seasonal-flu-vaccine-uptake-in-children-of-school-age-monthly-data-2020-to-2021
   Google Scholar
• UK Health Security Agency. Seasonal influenza vaccine uptake in children of school age. [cited 2023 Feb 23]. Avilable from: https://www.gov.uk/government/statistics/seasonal-flu-vaccine-uptake-in-children-of-school-age-monthly-data-2021-to-2022
   Google Scholar
• Jin H, Subbarao K. Live attenuated influenza vaccine. In: Oldstone MBA, Compans RW, editors. Influenza pathogenesis and control - volume II. Cham: Springer International Publishing; 2015. p. 181–204.
   Google Scholar
• Del Giudice G, Rappuoli R. Inactivated and adjuvanted influenza vaccines. In: Oldstone MBA, Compans RW, editors. Influenza pathogenesis and control - volume II. Cham: Springer International Publishing; 2015. p. 151–180.
   Google Scholar
• Keshavarz M, Mirzaei H, Salemi M, et al. Influenza vaccine: where are we and where do we go? Rev Med Virol. 2019;29(1):e2014.
   PubMed Web of Science ®Google Scholar
• Meyer R, De Koker C, Dziubak R, et al. Malnutrition in children with food allergies in the UK. J Hum Nutr Diet. 2014;27(3):227–235.
   PubMed Web of Science ®Google Scholar
• Ambrose CS, Levin MJ. The rationale for quadrivalent influenza vaccines. Hum Vaccin Immunother. 2012 Jan;8(1):81–88.
   PubMed Web of Science ®Google Scholar
• Baxter D. Evaluating the case for trivalent or quadrivalent influenza vaccines. Hum Vaccin Immunother. 2016;12(10):2712–2717.
   PubMed Web of Science ®Google Scholar
• Kawai S, Nanri S, Ban E, et al. Influenza vaccination of schoolchildren and influenza outbreaks in a school. Clin Infect Dis. 2011;53(2):130–136.
   PubMed Web of Science ®Google Scholar
• CDC. Past weekly surveillance reports. national center for immunization and respiratory diseases; 2022. [cited 2023 Feb 23]. Available from: https://www.cdc.gov/flu/weekly/pastreports.htm
   Google Scholar
• Bodewes R, de Mutsert G, van der Klis FR, et al. Prevalence of antibodies against seasonal influenza A and B viruses in children in Netherlands. Clin Vaccine Immunol. 2011;18(3):469–476.
   PubMed Web of Science ®Google Scholar
• WHO. Global influenza programme. In: Organization WH, editor. 2022. [cited 2023 Feb 23]. Available from: https://www.who.int/teams/global-influenza-programme/vaccines
   Google Scholar
• Influenza vaccine. In: Formulary NBN, editor. UK2022. [cited 2023 Feb 23]. Available from: https://bnf.nice.org.uk/drugs/influenza-vaccine/
   Google Scholar
• Katz JM, Hancock K, Xu X. Serologic assays for influenza surveillance, diagnosis and vaccine evaluation. Expert Rev Anti Infect Ther. 2011;9(6):669–683.
   PubMed Web of Science ®Google Scholar
• Pavlova S, D’Alessio F, Houard S, et al. Workshop report: immunoassay standardisation for “universal” influenza vaccines. Influenza Other Respir Viruses. 2017;11(3):194–201.
   PubMed Web of Science ®Google Scholar
• Cann AJ. Chapter 1 - Introduction. In: Cann AJ, editor. Principles of molecular virology (sixth edition). Boston: Academic Press; 2016. p. 1–25.
   Google Scholar
• Krammer F, Weir JP, Engelhardt O, et al. Meeting report and review: immunological assays and correlates of protection for next-generation influenza vaccines. Influenza Other Respir Viruses. 2020;14(2):237–243.
   PubMed Web of Science ®Google Scholar
• Hobson D, Curry RL, Beare AS, et al. The role of serum haemagglutination-inhibiting antibody in protection against challenge infection with influenza A2 and B viruses. J Hyg (Lond). 1972;70(4):767–777.
   PubMedGoogle Scholar
• Cox RJ. Correlates of protection to influenza virus, where do we go from here? Hum Vaccin Immunother. 2013;9(2):405–408.
   PubMed Web of Science ®Google Scholar
• Tam JS, Capeding MR, Lum LC, et al. Efficacy and safety of a live attenuated, cold-adapted influenza vaccine, trivalent against culture-confirmed influenza in young children in Asia. Pediatr Infect Dis J. 2007;26(7):619–628.
   PubMed Web of Science ®Google Scholar
• Vesikari T, Fleming DM, Aristegui JF, et al. Safety, efficacy, and effectiveness of cold-adapted influenza vaccine-trivalent against community-acquired, culture-confirmed influenza in young children attending day care. Pediatrics. 2006;118(6):2298–2312.
   PubMed Web of Science ®Google Scholar
• Vesikari T, Knuf M, Wutzler P, et al. Oil-in-water emulsion adjuvant with influenza vaccine in young children. N Engl J Med. 2011;365(15):1406–1416.
   PubMed Web of Science ®Google Scholar
• Niang MN, Sugimoto JD, Diallo A, et al. Estimates of inactivated influenza vaccine effectiveness among children in Senegal: results from 2 consecutive cluster-randomized controlled trials in 2010 and 2011. Clin Infect Dis. 2021;72(12):e959–e969.
   PubMed Web of Science ®Google Scholar
• Diallo A, Diop OM, Diop D, et al., Effectiveness of seasonal influenza vaccination in children in Senegal during a year of vaccine mismatch: a cluster-randomized trial. Clin Infect Dis. 2019. 69(10): 1780–1788.
   PubMed Web of Science ®Google Scholar
• Pepin S, Dupuy M, Borja-Tabora CFC, et al. Efficacy, immunogenicity, and safety of a quadrivalent inactivated influenza vaccine in children aged 6-35 months: a multi-season randomised placebo-controlled trial in the Northern and Southern Hemispheres. Vaccine. 2019;37(13):1876–1884.
   PubMed Web of Science ®Google Scholar
• Claeys C, Zaman K, Dbaibo G, et al. Prevention of vaccine-matched and mismatched influenza in children aged 6–35 months: a multinational randomised trial across five influenza seasons. Lancet Child Adolesc Health. 2018;2(5):338–349.
   PubMedGoogle Scholar
• Esposito S, Nauta J, Lapini G, et al., Efficacy and safety of a quadrivalent influenza vaccine in children aged 6-35 months: a global, multiseasonal, controlled, randomized phase III study. Vaccine. 2022. 40(18): 2626–2634.
   PubMed Web of Science ®Google Scholar
• Pepin S, Samson SI, Alvarez FP, et al. Impact of a quadrivalent inactivated influenza vaccine on influenza-associated complications and health care use in children aged 6 to 35 months: analysis of data from a phase III trial in the Northern and Southern Hemispheres. Vaccine. 2019;37(13):1885–1888.
   PubMed Web of Science ®Google Scholar
• Dbaibo G, Amanullah A, Claeys C, et al. Quadrivalent influenza vaccine prevents illness and reduces healthcare utilization across diverse geographic regions during five influenza seasons: a randomized clinical trial. Pediatr Infect Dis J. 2020;39(1):e1–e10.
   PubMed Web of Science ®Google Scholar
• Baum U, Kulathinal S, Auranen K, et al., Effectiveness of 2 Influenza Vaccines in Nationwide Cohorts of Finnish 2-Year-Old Children in the Seasons 2015-2016 Through 2017-2018. Clin Infect Dis. 2020. 71(8): e255–e261.
   PubMed Web of Science ®Google Scholar
• Vesikari T, Pellegrini M, Karvonen A, et al. Enhanced immunogenicity of seasonal influenza vaccines in young children using MF59 adjuvant. Pediatr Infect Dis J. 2009;28(7):563–571.
   PubMed Web of Science ®Google Scholar
• Carmona Martinez A, Salamanca de la Cueva I, Boutet P, et al. A phase 1, open-label safety and immunogenicity study of an AS03-adjuvanted trivalent inactivated influenza vaccine in children aged 6 to 35 months. Hum Vaccin Immunother. 2014;10(7):1959–1968.
   PubMed Web of Science ®Google Scholar
• Langley JM, Vanderkooi OG, Garfield HA, et al., Immunogenicity and safety of 2 dose levels of a thimerosal-free trivalent seasonal influenza vaccine in children aged 6-35 months: a randomized, controlled trial. J Pediatric Infect Dis Soc. 2012. 1(1): 55–63.
   PubMedGoogle Scholar
• Langley JM, Carmona Martinez A, Chatterjee A, et al. Immunogenicity and safety of an inactivated quadrivalent influenza vaccine candidate: a phase III randomized controlled trial in children. J Infect Dis. 2013;208(4):544–553.
   PubMed Web of Science ®Google Scholar
• Robertson CA, Mercer M, Selmani A, et al. Safety and immunogenicity of a full-dose, split-virion, inactivated, quadrivalent influenza vaccine in healthy children 6-35 months of age: a randomized controlled clinical trial. Pediatr Infect Dis J. 2019;38(3):323–328.
   PubMed Web of Science ®Google Scholar
• Statler VA, Albano FR, Airey J, et al. Immunogenicity and safety of a quadrivalent inactivated influenza vaccine in children 6-59 months of age: a phase 3, randomized, noninferiority study. Vaccine. 2019;37(2):343–351.
   PubMed Web of Science ®Google Scholar
• Eun BW, Lee TJ, Lee J, et al. A randomized, double-blind, active-controlled Phase III trial of a cell culture-derived quadrivalent inactivated influenza vaccine in healthy South Korean children and adolescents 6 months to 18 years of age. Pediatr Infect Dis J. 2019;38(9):e209–e215.
   PubMed Web of Science ®Google Scholar
• Wang L, Chandrasekaran V, Domachowske JB, et al. Immunogenicity and safety of an inactivated quadrivalent influenza vaccine in US children 6-35 months of age during 2013-2014: results from a phase II randomized trial. J Pediatric Infect Dis Soc. 2016;5(2):170–179.
   PubMed Web of Science ®Google Scholar
• Langley JM, Wang L, Aggarwal N, et al. Immunogenicity and reactogenicity of an inactivated quadrivalent influenza vaccine administered intramuscularly to children 6 to 35 months of age in 2012–2013: a randomized, double-blind, controlled, multicenter, multicountry, clinical trial. J Pediatric Infect Dis Soc. 2015;4(3):242–251.
   PubMed Web of Science ®Google Scholar
• Hu Y, Shao M, Hu Y, et al. Immunogenicity and safety of an inactivated quadrivalent influenza vaccine: a randomized, double-blind, controlled phase III clinical trial in children aged 6-35 months in China. Hum Vaccin Immunother. 2020;16(7):1691–1698.
   PubMed Web of Science ®Google Scholar
• Wood NJ, Blyth CC, Willis GA, et al. The safety of seasonal influenza vaccines in Australian children in 2013. Med J Aust. 2014;201(10):596–600.
   PubMed Web of Science ®Google Scholar
• Thiem VD, Chabanon AL, Fournier M, et al. Safety of a quadrivalent influenza vaccine in Vietnamese healthy subjects aged 6 months and older. Hum Vaccin Immunother. 2021;17(3):690–693.
   PubMed Web of Science ®Google Scholar
• Principi N, Camilloni B, Esposito S. ESCMID Vaccine Study Group (EVASG). Influenza immunization policies: which could be the main reasons for differences among countries? Hum Vaccin Immunother. 2018 Mar 4;14(3):684–692.
   PubMed Web of Science ®Google Scholar
• Baguelin M, Flasche S, Camacho A, et al., Assessing optimal target populations for influenza vaccination programmes: an evidence synthesis and modelling study. PLoS Med. 2013. 10(10): e1001527.
   PubMed Web of Science ®Google Scholar
• Heikkinen T, Tsolia M, Finn A. Vaccination of healthy children against seasonal influenza: a European perspective. Pediatr Infect Dis J. 2013;32(8):881–888.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Influenza Vaccines: WHO position paper 2005. [cited 2023 Feb 23]. Available from: https://www.who.int/publications/i/item/WER8033
   Google Scholar
• Ramet J, Weil-Olivier C, Sedlak W. Influenza vaccination: the paediatric perspective. Vaccine. 2007;25(5):780–787.
   PubMed Web of Science ®Google Scholar